Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon’s Syndrome of Unknown Cause

Gustavo C. Santo a Inês Baldeiras b,h Rita Guerreiro c–e Joana A. Ribeiro a Rosário Cunha f Taryn Youngstein g Sira Nanthapisal j, k João Leitão h Carolina Fernandes a Francisco Caramelo l Maria do Rosário Almeida h José Brás c–e Isabel Santana a, b, h Centro Hospitalar e Universitário de Coimbra

aDepartment of Neurology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; bFaculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal; cUK Dementia Research Institute, University College London, London, UK; dDepartment of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK; eDepartment of Medical Sciences and Institute of Biomedicine, iBiMED, University of Aveiro, Aveiro, Portugal; fDepartment of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; gNational Amyloidosis Centre, UCL School of Medicine, Royal Free Hospital, London, UK; hCentro de Neurociências e Biologia Celular da Universidade de Coimbra, Coimbra, Portugal; iLaboratório de Bioestatística e Informática Médica da Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal; jUCL Great Ormond Street Institute of Child Health, London, UK; kThammasat University, Bangkok, Thailand

Keywords
Sneddon’s syndrome · Cat eye syndrome chromosome region candidate 1 · Deficiency of adenosine deaminase 2 · Adenosine deaminase 2 · Immunoglobulin M

Abstract
Background: The association that exists between livedo reticularis (LR) and stroke is known as Sneddon’s syndrome (SnS). The disorder is classified as primary SnS (PSnS), if the cause remains unknown and secondary SnS. The condition is rare and it occurs mainly sporadically. In 2014, 2 independent teams described a new genetic disorder with childhood-onset, which was called deficiency of adenosine deaminase 2 (DADA2), characterized by recurrent fevers and vascular pathologic features that included LR and stroke. All the patients carried recessively inherited mutations in cat eye syndrome chromosome region candidate 1 gene (CECR1), encoding the adenosine deaminase 2 (ADA2) protein. Genetic testing is the standard for the diagnosis of DADA2. However, the diagnostic accuracy of more affordable laboratorial analysis in CECR1-mutated individuals remains to be established. We aim to determine whether plasma ADA2 activity and serum immunoglobulin M (IgM) levels can distinguish (1) DADA2 from other adult patients within the SnS spectrum, and (2) healthy CECR1 heterozygous (HHZ) from healthy controls (HC).

Methods: ADA2 activity in plasma and serum IgM concentrations was measured in adult patients within the SnS spectrum, healthy first-degree relatives and HC. Genetic results were used as the reference standard. The primary outcome measures were sensitivity and specificity.

G.C.S., I.B., and R.G. contributed equally to the manuscript.
specificity derived from receiver operating curve analysis.

Results: A total of 73 participants were included in the study: 26 patients with PSnS with no CECR1 mutation (PSnS), 6 bi-allelic (DADA2 patients) and 7 HHZ CECR1 mutations and 34 HC. Plasma ADA2 activity and serum IgM levels were significantly lower in DADA2 patients than in PSnS. With the use of the best indexes, plasma ADA2 activity differentiated PSnS from DADA2 with a sensitivity and specificity of 100.0% and HHZ from HC with a sensitivity of 97.1% and specificity of 85.7%. Serum IgM levels also differentiated PSnS from DADA2 with a sensitivity of 85.2% and specificity of 83.3%.

Conclusion: Serum IgM levels might be used as a triage tool and plasma ADA2 activity performs perfectly as a diagnostic test for DADA2 in adult patients within the SnS spectrum. ADA2 activity in plasma also reliably distinguishes HHZ from HC.

Introduction

The association that exists between livedo reticularis (LR) and stroke is known as Sneddon’s syndrome (SnS) [1].

The disorder is classified as primary SnS (PSnS) if the cause remains unknown, or secondary SnS, which usually occurs as part of well-known autoimmune disorders (antiphospholipid syndrome with/without coexisting systemic lupus erythematosus) [2].

SnS is rare and it occurs mainly sporadically [3]. In 2014, 2 independent teams [4, 5] described a new genetic disorder with childhood-onset, which was called Deficiency of adenosine deaminase (DADA2), characterized by recurrent fevers and vascular pathologic features that included LR and stroke. All the patients carried recessively inherited mutations in Cat Eye Syndrome Chromosome Region Candidate 1 gene (CECR1), encoding the adenosine deaminase 2 (ADA2) protein. Laboratory manifestations included reduced active ADA2 concentration in plasma and mild immunodeficiency. In the same year, Bras et al. [6] identified a compound heterozygous missense mutation in CECRI in a Portuguese SnS family with adult onset, previously reported in 2002 [7, 8], expanding the phenotype associated with mutations in this gene to include later onsets of disease.

Genetic testing is the standard for the diagnosis of DADA2. However, the diagnostic accuracy of more affordable laboratorial analysis in CECRI mutated individuals remains to be established. The purpose of this study was therefore to determine whether plasma ADA2 activity and serum immunoglobulin M (IgM) levels can distinguish DADA2 from other adult patients within the SnS spectrum and healthy CECRI heterozygous (HHZ) from healthy controls (HC).

Methods

Patient Selection

All consecutive individuals within SnS’s spectrum were collected in a prospective longitudinal database and full written informed consent was obtained from all participants. The study protocol was approved by the local Ethics Committee (Faculdade de Medicina da Universidade de Coimbra, Proc. CE-126/2015, approved November 30, 2015). The majority of participants were identified locally, in a tertiary University Hospital in Portugal. Three were referred by the National Amyloidosis Centre, UCL Division of Medicine, London.

Inclusion criteria were as follows: patients aged 18 years or older, and SnS, both sporadic or familial; patients with LR and family history of SnS; healthy volunteers who were first-degree relatives of patients with familial SnS. We also included healthy volunteer individuals recruited by advertisement. Controls had no relationship with the other participants and no history of LR, cerebrovascular disease or other neurological illness.

SnS was defined by the association of a widespread LR involving the trunk and/or the buttock and/or the legs and at least one clinical cerebral event (either ischemic or haemorrhagic stroke, transient ischemic attack or a silent vascular brain lesion detected on MRI). Patients were excluded if they presented: (1) at least one of the clinical criteria and one of the laboratory criteria for Antiphospholipid Antibody Syndrome [9] and/or (2) clinical and immunological criteria for Systemic Lupus Erythematosus [10] or (3) any thrombophilic state.

Demographic and clinical features, including vascular risk factors and laboratorial data, were collected from all participants in a standardized format.

All the technicians involved in the study were blinded for the clinical features and any other laboratorial results.

Procedures

Total ADA and ADA2 Activity in Plasma

Blood samples were collected from all participants into lithium heparin tubes. The tubes were centrifuged at 1,500 g at 4 °C for 10 min and plasma was separated and frozen at −80 °C until analysis.

Total ADA was determined through a commercial method (Diazyme) based on the conversion of adenosine into inosine and further into hypoxanthine (by purine nucleoside phosphorylase) and into uric acid and hydrogen peroxide (by xanthine oxidase). The conversion of hydrogen peroxide by peroxidase into the quinone dyes 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine was then monitored at 550 nm in a thermostatted spectrophotometer at 37°C (UVIKON 933 UV/Visible). ADA2 activity was measured by the same method, in the presence of 0.1 mM of erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA, Sigma), a potent selective inhibitor of ADA1 [11]. ADA1 activity was then calculated by subtracting ADA2 activity from total ADA activity.

Santo et al.
Each sample was run in duplicate and 2 control samples (with high and low levels of ADA activity) were assayed in each day for internal quality control. The intra-assay coefficient variation, calculated from 6 repeats, was 6.4%, and the inter-assay coefficient variation, calculated for 13 runs performed, was 5.5%.

Quantitative Assessment of Serum IgM
A nephelometric method was used for the measurement of IgM levels in serum samples, using the same technical conditions (performed on the same day and working session, and using the same batch of reagents, NASIGM, Siemens HDP). The IgM contained in the human serum form immune complexes with specific antibodies that are present in the reagent. These complexes scatter a beam of light passed through the sample and the intensity of the scattered light is proportional to the concentration of IgM in the sample [12]. The results were then evaluated by comparison with a standard of known concentration.

Genetic Analyses
DNA was extracted according to manufacturer’s instructions from saliva samples collected using the Oragene DNA (OG-500, DNA Genotek) kit or from blood samples using the GE Healthcare Nucleon™ BAC3 Genomic DNA Extraction Kit. Exome and Sanger sequencing were used to identify mutations and variants in the CECR1 gene in all the patient’s groups studied.

Exome sequencing was initially performed in 2 siblings from a Portuguese SS family and results were reported in Bras et al. [6] Exome sequencing was also performed in 14 Portuguese additional cases (4 familial and 10 sporadic) by preparing genomic DNA and capturing it using Agilent’s SureSelect version 4 capture kit, according to manufacturer’s instructions. Sequencing was performed in Illumina’s HiSeq2000 using 100 bp paired-end reads and data were analyzed after quality control and following standard procedures (online suppl. data; for all online suppl. material, see www.karger.com/doi/10.1159/000495794). Variants in CECR1 were extracted and compared to databases of human genetic variability.

Sanger sequencing was used in the remaining samples. For this, primers for all exons of CECR1 were designed using Primer3. Details for the PCR conditions, electrophoresis of PCR products and Sanger sequencing procedures used and primer design are provided in the online supplementary material. Sanger sequencing of CECR1 was also performed in the 3 patients that were referred by the National Amyloidosis Centre, UCL Division of Medicine, London. This was done at Great Ormond Street Hospital’s Foundation Trust, using standard procedures.

Statistical Analysis
The results of genetic testing were the reference standard for the diagnosis of DADA2.

Baseline characteristics are presented as frequency (percentage) for dichotomous variables and mean ± SD for continuous variables.

A 2-way Mann-Whitney U test was used to compare means between groups.

Area under the curve (AUC) for receiver operating characteristic (ROC) analysis was used to determine diagnostic accuracy (sensitivity, specificity, positive and negative predictive values, accuracy) for both tests (serum IgM levels and plasma ADA2 activity) with 95% CI. Cut-off points were set to minimize the difference between sensitivity and specificity (Youden index). Statistical significance was assumed at p < 0.05.

Results
Participants and Laboratorial Parameters
Between January 2, 2016 and December 23, 2017, we screened 96 potential individuals; 73 of them (mean age 41.5 ± 11.0, male 31.5%) met the inclusion criteria and were therefore enrolled in the study. Four subjects did not consent to participate and 19 were excluded as they had secondary SnS. Twenty-six patients with no CECR1 mutation (age 45.1 ± 9.8), 6 bi-allelic (DADA2 patients; age 41.7 ± 12.1) and 7 HHZ CECR1 mutated individuals (age 32.0 ± 13.9) and 34 HC (age 40.6 ± 10.2) were included in the study (Fig. 1). The CECR1 mutations identified in the cohort studied and the coding variants identified in the individuals without CECR1 mutations are shown in online supplementary Tables S2, and S3 respectively.

General demographic and clinical characteristics of the study population are presented in Table 1.

Total ADA, ADA2 and ADA1 activities, as well as serum IgM levels of the studied population are shown in Table 2. DADA2 patients had significantly lower serum IgM levels (p = 0.002), as well as significantly reduced activity of total ADA (p < 0.001) and ADA2 (p < 0.001) compared to P5nS patients. In fact, ADA2 activity was almost completely abolished in bi-allelic mutation carriers, ranging from 0 to 0.34 U/L and showing no overlap with patients without mutation (range 5.15–25.41 U/L; Fig. 2b). For IgM, although a statistically significant difference was seen, still some overlap between groups remained (Fig. 2a). In HHZ, IgM levels were not significantly different from HCs (p = 0.225; Fig. 2a); however, a significant reduction of both total ADA and ADA2 activity was seen (p = 0.004 and p < 0.001, respectively, vs. HC). The reduction in ADA2 activity in HHZ was not as strong as in DADA2 patients (activity levels ranging between 1.50 and 5.62 U/L), and therefore some overlap with activity levels determined in HCs was detected (Fig. 2b). No statistical differences were found in mean IgM levels or total ADA and ADA2 activity between P5nS and HC. ADA1 activity was similar between all groups.

Diagnostic Accuracy of Plasma ADA2 Activity and Serum IgM Levels
Differentiating DADA2 from P5nS
An ROC curve was plotted to compare how effectively plasma ADA2 activity and serum IgM levels distinguished

ADA2 and IgM Differentiate Adult SnS

Cerebrovasc Dis 2018;46:257–264
DOI: 10.1159/000495794
patients with DADA2 from PSnS (Fig. 3a). Accuracy parameters for this distinction are shown in Table 3. For serum IgM levels, at the best cut-off of 0.65 g/L, the AUC was 0.904 (95% CI 0.775–1.000), sensitivity of 85.2%, and specificity of 83.3% ($p = 0.002$). For plasma ADA2 activity, the best cut-off was fixed at 2.745 U/L, with an AUC of 1.00 (95% CI 1.000–1.000), sensitivity of 100.0% and specificity of 100.0% ($p < 0.001$).

Differentiating HHZ from HC
To evaluate the diagnostic accuracy of these laboratorial parameters in differentiating HHZ from HC, an ROC curve was also employed (Fig. 3b) and statistical parameters are shown in Table 3. For serum IgM levels, the ROC curve was not statistically different from the reference curve ($p = 0.225$). Conversely, for plasma ADA2 activity, ROC curve analysis fixed the best cut-
off at 3.77 U/L, with an AUC of 0.971 (95% CI 0.923–1.00), sensitivity of 97.1% and specificity of 85.7% (p < 0.001).

**Discussion**

In the present study, we found that in adult SnS patients, plasma ADA2 activity was significantly lower in DADA2 in comparison with SnS patients. An extremely low, or even absent, activity of ADA2 in paediatric patients with DADA2 had previously been shown in other studies [13–15]. These authors have previously shown a statistically significant difference between ADA2 activity in DADA2 patients in comparison to HC, but the relation with sporadic patients exhibiting a similar clinical phenotype was not tested. In fact, the diagnostic accuracy of ADA2 activity in differentiating DADA2 from sporadic SnS in adults had never been investigated. In our study, we show that, at the best cut-off of 2.745 U/L, plasma ADA2 activity distinguished DADA2 patients from SnS with 100% sensitivity and 100% specificity, which suggests that it fits perfectly as a diagnostic test.

### Table 2. ADA-T, ADA2 and ADA1 activity in plasma and serum IgM concentration of the studied population

<table>
<thead>
<tr>
<th></th>
<th>PSnS</th>
<th>DADA2</th>
<th>p value, PSnS vs. DADA2</th>
<th>HHZ</th>
<th>HC</th>
<th>p value, HHZ vs. HC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>26</td>
<td>6</td>
<td></td>
<td>7</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>ADA-T, U/L</td>
<td>14.5±5.4</td>
<td>4.0±1.6</td>
<td>&lt;0.001</td>
<td>7.8±2.9</td>
<td>12.5±3.3</td>
<td>0.004</td>
</tr>
<tr>
<td>ADA2, U/L</td>
<td>10.3±4.6</td>
<td>0.1±0.2</td>
<td>&lt;0.001</td>
<td>3.0±1.4</td>
<td>8.9±3.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ADA1, U/L</td>
<td>4.2±1.2</td>
<td>3.9±1.6</td>
<td>0.847</td>
<td>4.8±1.9</td>
<td>3.6±1.3</td>
<td>0.089</td>
</tr>
<tr>
<td>IgM, g/L</td>
<td>1.3±0.7</td>
<td>0.5±0.3</td>
<td>0.003</td>
<td>0.9±0.5</td>
<td>1.1±0.5</td>
<td>0.225</td>
</tr>
</tbody>
</table>

Data is shown as mean ± SD.

ADA-T, total ADA activity in plasma; ADA2, ADA2 activity in plasma; ADA1, ADA1 activity in plasma; ADA, adenosine deaminase; PSnS, primary Sneddon’s syndrome; DADA2, deficiency of adenosine deaminase 2; HHZ, healthy CECR1 heterozygous; HC, healthy controls; CECR1, cat eye syndrome chromosome region candidate 1 gene; ADA1, adenosine deaminase 1; ADA2, adenosine deaminase 2; IgM, immunoglobulin M.
Although the pathogenesis of DADA2 is still unclear, there is some evidence that the underlying mechanism involves the loss-of-function mutations in CECR1 encoding the ADA2 protein [5]. ADA2 is known to be produced by myeloid cells and is a growth factor for endothelial and leukocyte development [4]. In fact, despite CECR1 not being expressed in the endothelium, DADA2 leads to a defect in endothelial instability and integrity [16] in the small and medium vessels of patients with ADA2 mutations as well as impairment of M2 macrophage differen-

**Table 3.** AUC, sensitivity, specificity, and positive and negative predictive values for receiver operating characteristic curves using best laboratorial tests

<table>
<thead>
<tr>
<th></th>
<th>PSnS vs. DADA2</th>
<th>HHZ vs. HC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADA2 activity in plasma, U/L</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC (95% CI)</td>
<td>1.00 (1.00–1.00)</td>
<td>0.971 (0.923–1.00)</td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>100</td>
<td>97.1</td>
</tr>
<tr>
<td>Specificity, %</td>
<td>100</td>
<td>85.7</td>
</tr>
<tr>
<td>PPV, % (95% CI)</td>
<td>100 (100.0–100.0)</td>
<td>71.4 (38.1–91.0)</td>
</tr>
<tr>
<td>NPV, % (95% CI)</td>
<td>100 (100.0–100.0)</td>
<td>97.7 (87.8–99.6)</td>
</tr>
<tr>
<td>Accuracy, % (95% CI)</td>
<td>100</td>
<td>94.1 (83.8–98.8)</td>
</tr>
<tr>
<td><strong>Serum IgM concentration, g/L</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC (95% CI)</td>
<td>0.901 (0.767–1.000)</td>
<td>0.647 (0.386–0.908)</td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>85.2</td>
<td>67.6</td>
</tr>
<tr>
<td>Specificity, %</td>
<td>83.3</td>
<td>71.4</td>
</tr>
<tr>
<td>PPV, % (95% CI)</td>
<td>83.3 (40.2–97.4)</td>
<td>71.4 (35.5–91.9)</td>
</tr>
<tr>
<td>NPV, % (95% CI)</td>
<td>85.2 (73.4–92.3)</td>
<td>67.6 (59.6–74.8)</td>
</tr>
<tr>
<td>Accuracy, % (95% CI)</td>
<td>84.8 (68.1–94.9)</td>
<td>68.3 (51.3–86.7)</td>
</tr>
</tbody>
</table>

PSnS, primary Sneddon’s syndrome; DADA2, deficiency of adenosine deaminase 2; HHZ, healthy CECR1 heterozygous; HC, healthy controls; CECR1, cat eye syndrome chromosome region 1 gene; AUC, area under the curve; ADA2, adenosine deaminase 2; PPV, positive predictive value; NPV, negative predictive value; IgM, immunoglobulin M.
tiation [4]. Once secreted, it induces the differentiation of monocytes into macrophages, possibly by binding proteoglycan-like structures on the cellular surface [17]. Moreover, ADA2 seems to be involved in the balance between pro-inflammatory (M1) and anti-inflammatory (M2) monocytes. Its absence has been associated with a defect in differentiation of M2 macrophages, which leads to a prevalence of pro-inflammatory M1 cells [18], establishing a vicious circle of vasculopathy and inflammation [4].

As previously stated, a mild immunodeficiency can also be observed in DADA2, and indeed, very recently, Schepp et al. [19] suggested that patients with antibody deficiency should be screened for DADA2. Some patients present hypogammaglobulinemia that may affect IgM or all Ig subclasses [18]. In our study, for serum IgM levels, at the best cut-off of 0.65 g/L, the AUC to differentiate between DADA2 and sporadic PSnS patients was 0.904 with a sensitivity of 85.2%, and specificity of 83.3%, which suggests that it has an excellent diagnostic accuracy.

These results are particularly relevant, since recent observational studies have reported that some drugs (anti-TNF-α with or without daily prednisolone and/or an alternative disease modifying anti-rheumatic drug) [14] seem to be effective, and hematopoietic stem cell transplantation might represent a potential definitive treatment for DADA2 [16].

It should also be mentioned that, although the clinical phenotype of monoallelic CECR1 mutated subjects is not clear, some authors report a full picture of a DADA2-like disease in some of those individuals [18]. This was not the case for individuals found in this study as heterozygous carriers of CECR1 mutations. It is possible though that these subjects will come to develop some features of the disease as they age.

In the present study, for plasma ADA2 activity, at the best cut-off of 3.77 U/L, the AUC for differentiating between HHZ and HC was 0.971, with a sensitivity of 97.1% and a specificity of 85.7%, which corresponds to an almost perfect test. Other studies have reported on ADA2 activity in CECR1 single-mutation carriers, and while some authors showed a reduction to approximately half [4, 19] other reported no difference in relation to HCs [5, 14]. Meanwhile, for serum IgM levels, at the best cut-off of 0.92 g/L, AUC was 0.647 (p = 0.225, 95% CI 0.386–0.908), with a sensitivity of 67.6%, and specificity of 71.4%, which suggests that this test does not accurately identify CECR1 heterozygous.

Our study has some important strengths. First, it was prospectively designed and the procedures of screening and confirmation were standardized according to the protocol. Second, the plasma ADA2 activity and the serum IgM measurements were determined in all subjects and each of the tests was performed by the same raters, using the same method and under equal technical conditions. Third and the most relevant, we tried to establish, for the first time, the accuracy of these laboratorial tests to distinguish between adult DADA2 and PSnS but also to differentiate HHZ individuals from HCs, together with the optimal cut-off points. Notwithstanding, these findings should be confirmed in larger multicentre studies, that would encompass both adult and paediatric DADA2 patients. As other authors have reported, ADA2 activity might be lower in adults that in children [4, 14] and an age-adjusted cut-off value would probably be needed. In our study, as in the study of Schepp et al. [19], there was no evidence of an influence of the position and type of mutation on ADA2 enzymatic activity. However, this should also be confirmed by the inclusion of patients with other CECR1 mutations.

This study also has some limitations. As it is presumably a rare disorder, the number of patients with bi-allelic and heterozygous mutations was low, which might have biased the data interpretation. For the same reason, we did not perform genetic testing in healthy volunteers.

In conclusion, serum IgM measurement has a potential role as a primary screening tool and plasma ADA2 activity might be an excellent diagnostic test for DADA2 in patients with SnS of unknown cause, making them suitable for implementation in clinical practice. ADA2 activity in plasma also provides high accuracy to identify CECR1 heterozygous individuals.

Acknowledgements

The authors would like to thank Graça Fernandes from the nurse staff and Rui Pascoal for the technical assistance.

Disclosure Statement

The authors have no conflicts of interest to declare relevant to the manuscript.

Funding Source

R.G. and J.B. work is funded by Research Fellowships from the Alzheimer’s Society and J.L. by the Portuguese Foundation for Science and Technology (ref. PD/BD/13108/2017).
Authors Contribution


References